The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

CAR T-cell therapy

CAR T-cell therapy

In chimeric antigen receptor (CAR) T-cell therapy, T cells are taken from the patient, genetically modified to express the CAR construct, and then infused back into the patient. The CAR T cells target and kill cancer cells, which express the targeted cell surface antigen. Whilst CAR T-cell therapy is less clinically advanced in AML compared to other hematological malignancies, there are CAR T-cell products targeting antigens, such as CD123 and CD33, in clinical development.

| |

All Interventions